Structure-Based Enhancement Techniques

Microfabricated Microneedles

Microfabricated microneedles are devices which are hybrids of the hypodermic needle and transdermal patch through the use of microscopic needles that can deliver the drug effectively (like a hypodermic needle). Their small size offers the potential advantages of delivering large molecules across the stratum corneum without extreme pain to the patients. The first microneedles systems consisted of a drug reservoir and a plurality of projections (microneedles) extending from the reservoir, which penetrate the stratum corneum and epidermis to deliver the drug. The microneedle concept employs an array of micron-scale needles that can deliver drug into the epidermis and dermis, which ultimately leads to uptake by the capillaries for systemic delivery but not so far that microneedles hit the nerves. This is the reason for the device being less painful to patients. The most common material used for microfabrication of needles is silicon. These microneedles have extremely sharp tips (radius of curvature, <1µm) that facilitate easy piercing of the skin. Individual silicon needles measuring approximately 150 µm in length and with 80 µm base diameter are fabricated onto arrays of approximately 400 microneedles (approx. 3 X 3 mm). Needles with hollow centers have also been produced, each containing a bore of 5-70 µm (depending on the required design) through which drug can be administered. A broad range of compounds such as calcein (623 Da), insulin (6000Da), BSA (66000Da) and polymeric nanoparticles are delivered at significant rates through skin permeabilized by microfabricated microneedles.

Metered-Dose Transdermal Spray (MDTS)

Metered-dose transdermal spray (MDTSTM), originally developed at the Victorian College of Pharmacy [Monash University (Parkville Campus), Parkville, Victoria, Australia] and currently being commercialized by Acrux Limited [Melbourne, Victoria, Australia] has the potential to expand the growth of TDD systems by broadening patient acceptance and pharmaceutical applications for enhanced TDD. MDTS relies on the combination of a newly identified GRAS (generally recognized as safe) chemical penetration enhancer (AcrossTM) and the accurate and precise topical dosing of a volatile: nonvolatile vehicle. This MDTS can be classified, as an enhanced, passive TDD system. It is a topical solution made up of a volatile cum nonvolatile vehicle containing the drug dissolved as a single-phase solution. A finite metered - dose application of the formulation to intact skin results in subsequent evaporation of the volatile component of the vehicle, leaving the remaining nonvolatile penetration enhancer and drug to rapidly partition into the stratum corneum during the first minute after application, resulting in a stratum corneum reservoir of drug and enhancer. Following a once daily application of the MDTS, a sustained and enhanced penetration of the drug across the skin can be achieved from the stratum corneum reservoir. Different types of penetration enhancers, such as ethanol and azone, are commonly used. Clinical experience with estradiol-MDTS to post-menopausal women have shown increased higher plasma level of estradiol than the baseline value measured by radioimmunoassay.

The MDTS has the following potential advantages:

1. Enhanced passive tdds with little or no skin irritation primarily as a result of its non-occlusive nature.

2. Improved cosmetic acceptability

3. Dose flexibility

4. Simplicity of manufacture.

Ultrasound

Ultrasound (sonophoresis, phonophoresis and ultraphonophoresis) is a technique for increasing the skin permeation of drugs using ultrasound (20 KHZ to 16 MHZ) as a physical force. It is a combination of ultrasound therapy with topical drug therapy to achieve therapeutic drug concentrations at selected sites in the skin. In this technique, the drug is mixed with a coupling agent usually a gel but sometimes a cream or ointment is used which transfers ultrasonic energy from the device to the skin through this coupling agent. Application of low – frequency ultrasound (20 - 100 KHZ) enhances skin permeability more effectively than high – frequency ultrasound (1 - 16 MHZ). The mechanism of transdermal skin permeation involves disruption of the stratum corneum lipids, thus allowing the drug to pass through the skin. A corresponding reduction in skin resistance was observed due to cavitation, microstreaming and heat generation. Reverse ultrasound technology may also be used for the extraction of interstitial fluid samples for analysis.

Electroporation

This method involves the application of high voltage pulses to the skin, which has been suggested to induce formation of transient pores. High voltages in the form of direct current [DC (100 volts)] caused by electrical pulses with short treatment durations (milliseconds) are most frequently employed. Other parameters that affect delivery include pulse properties such as wave form, rate and number. The mechanism of penetration is the formation of transient pores due to electric pulses that subsequently allow the passage of macromolecules from the outside of the cell to the intracellular space via a combination of possible processes such as diffusion and local elctrophoresis. The electrical resistance of the skin is reported to drop as much as three orders of magnitude within microseconds of administration of an electric pulse. The technology has been successfully used to enhance the skin permeability of molecules with differing lipophilicity and size (i.e., small molecules, proteins, peptides and oligonucleotides) including biopharmaceuticals with molecular weights greater than 7KDa. Increase in transdermal penetration of up to 10 fold have been reported in vitro for various sizes of molecules such as metoprolol, lidocaine, tetracaine, vitamin C, timolol and fentanyl dyes, including calcein and methylene blue, and macromolecules up to 40 KDa including cyclosporineA, heparin, leutenising hormone releasing hormone, insulin, oligonucleotides and dextrans (MW 4.4 – 39 KDa).

Дата добавления: 2014-11-18